Eight-hour versus 24-h whole-blood hold before preparation of platelet concentrates by the platelet-rich plasma method

2014 ◽  
Vol 39 (4) ◽  
pp. 195
Author(s):  
GhadaM El-Gohary ◽  
AzzaS El-Danasoury ◽  
MahiraI El-Mogy ◽  
Amal Farouk ◽  
GhadaS Neseem
Transfusion ◽  
2006 ◽  
Vol 46 (4) ◽  
pp. 572-577 ◽  
Author(s):  
Gary Moroff ◽  
Linda Kline ◽  
Michelle Dabay ◽  
Suzanne Hunter ◽  
Adrienne Johnson ◽  
...  

Transfusion ◽  
2003 ◽  
Vol 43 (12) ◽  
pp. 1723-1728 ◽  
Author(s):  
Maria L. Lozano ◽  
Elena Pérez-Ceballos ◽  
Jose Rivera ◽  
Dragica Paunovic ◽  
Maria J. Candela ◽  
...  

Blood ◽  
1966 ◽  
Vol 27 (4) ◽  
pp. 449-459 ◽  
Author(s):  
FREDERICK A. FLATOW ◽  
EMIL J. FREIREICH

Abstract Platelet concentrates prepared in acidified plasma (pH 6.5-6.7) are superior to concentrates prepared by standard methods, and are 80-90 per cent as effective as platelet rich plasma (PRP). The use of excess citric acid to acidify plasma promotes resuspension of the concentrate by eliminating clumping, which is a major factor in the decreased effectiveness of standard concentrates. Analysis of posttransfusion recovery and survival of platelets reveals no evidence of platelet injury in an acid medium. Acidification of PRP inhibits the aggregation of platelets by adenosine diphosphate (ADP). The presence of endogenous ADP may be an important factor in clumping during standard concentrate preparation. A method of acidification of PRP using citric acid is described which allows preparation of an effective concentrate from fresh whole blood without subjecting the red cells to acid pH. Reconstitution of the acidified platelet poor plasma and its native red cells increases the citrate molarity by less than 6 per cent and results in minimal decrease in pH of the whole blood.


Vox Sanguinis ◽  
1995 ◽  
Vol 68 (2) ◽  
pp. 82-89 ◽  
Author(s):  
M.N. Boomgaard ◽  
C.W.N. Gouwerok ◽  
C.H. Palfenier ◽  
I.E. Pankalla-Blandeau ◽  
H.A. Veldman ◽  
...  

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 946-946 ◽  
Author(s):  
Sherrill J. Slichter ◽  
Doug Bolgiano ◽  
Jill Corson ◽  
Mary Kay Jones ◽  
Todd Christoffel ◽  
...  

Abstract Background: With the introduction of bacterial testing, extended storage of platelets is now possible as long as platelet viability is maintained. Although apheresis platelets have recently been licensed for seven days of storage, platelet concentrates are still only licensed for five days. We performed studies to determine the post-storage viability of platelets stored as concentrates. As yet, there are no established criteria for platelet viability that must be met at the end of storage. However, two different criteria for evaluating post-storage platelet viability have been suggested: compare the stored platelet results with each donor’s fresh platelet results; or establish a fixed platelet standard with an expected mean value along with the lower limit of the 95% confidence interval (lower 95% CI) of the mean. Methods: Forty-four normal volunteers donated a unit of whole blood, the whole blood was centrifuged to give platelet-rich plasma (PRP), and the PRP was then centrifuged to produce a platelet concentrate. The platelet concentrates were re-suspended and stored in either 100% plasma or in 20% plasma and 80% Plasmalyte (a platelet storage solution) for five to eight days in Terumo Teruflex bags. At the end of storage, a sample of blood was obtained from each volunteer to prepare fresh platelets to compare the results of a fresh platelet transfusion with the transfusion of the same volunteer’s stored platelets. The fresh and stored platelets were alternately radiolabeled with either 51Cr or 111In, re-injected into their volunteer donor, and serial blood samples were drawn from the volunteer after transfusion of the fresh and stored platelets to determine platelet recoveries and survivals. Results: Results are shown in Table 1. Conclusions: After seven days of storage in plasma, the platelets could qualify for standards of: 74% and 53% as a simple ratio of fresh to stored platelet recoveries and survivals, respectively; according to Dumont’s method of analysis (Transfusion, in press), achievable stored platelet recoveries would be 63% of fresh and survivals would be 40% of fresh; and as a fixed standard, platelet recoveries averaged 45% and survivals 4.4 days with lower 95% CI’s of 35% and 3.3 days, respectively. After eight days of storage in plasma, platelet recoveries and survivals gave unacceptable results. Instead of increasing or at least maintaining post-storage platelet viability, Plasmalyte markedly reduced platelet viability compared to plasma stored platelets at each storage interval. In Vivo Radiolabeled Autologous Platelet Recoveries and Survivals STORAGE CONDITIONS PLATELET RECOVERIES (%) PLATELET SURVIVALS (Days) Solution Time (Days) N Fresh Stored Fresh Stored Data are given as the average ±1 S.D. Plasma 5 10 62±12 55±11 7.7±1.5 6.1±1.0 Plasma 6 10 61±7 46±12 8.2±1.5 5.1±1.6 Plasmalyte 6 3 47±30 29±16 5.1±3.4 1.8±0.2 Plasma 7 10 61±11 45±14 8.3±1.0 4.4±1.5 Plasmalyte 7 5 62±17 30±12 7.4±0.6 2.2±1.1 Plasma 8 3 67±12 31±8 8.3±0.6 2.9±0.8 Plasmalyte 8 3 70±3 21±8 8.2±0.8 0.7±0.1


Vox Sanguinis ◽  
1995 ◽  
Vol 68 (2) ◽  
pp. 82-89 ◽  
Author(s):  
M. N. Boomgaard ◽  
C. W.N. Gouwerok ◽  
C.H. Palfenier ◽  
I.E. Pankalla-Blandeau ◽  
H.A. Veldman ◽  
...  

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1153-1153
Author(s):  
Hobl Eva-Luise ◽  
Petra Jilma-Stohlawetz ◽  
Ulla Derhaschnig ◽  
Schoergenhofer Christian ◽  
Michael Schwameis ◽  
...  

Abstract Background Patients on anti-platelet therapy have a higher incidence of bleeding complications and reversal of anti-platelet drug effects is an important issue in emergency situations. For old and conventional anti-coagulants, reversal strategies are established. However, there is no experience or recommendation how to antagonize the reversible and highly effective P2Y12-inhibitor ticagrelor and how to restore platelet function following ticagrelor dosing. The aim of this study was to investigate an ex vivo model to reverse the effects of ticagrelor and to estimate the optimal quantity of platelet transfusions required to normalize platelet aggregation. Methods Healthy volunteers (n=20) ingested a loading dose of 180 mg ticagrelor. Blood samples were obtained at baseline to gain autologous platelet rich plasma and to perform aggregation studies after 3h, i.e. at the time of expected maximal ticagrelor concentrations and maximimal platelet inhibition. To normalize platelet aggregation, increasing amounts of autologous platelet rich plasma (PRP) were added ex vivo to hirudin anti-coagulated blood, by spiking PRP into blood at ratios of 1:10, 1:5 and 1:3. Platelet aggregation was assessed by whole blood multiple electrode aggregometry (MEA; Multiplate). For interpretation of aggregation, we defined a cutoff level of 40 U (Units) as the lower limit of the normal range. Volunteers above this level were considered to exhibit normal platelet reactivity. Nonparametric tests were used and statistical comparisons were performed with the Friedman ANOVA, and the Wilcoxon test for post-hoc comparisons. A two-tailed p-value of less than 0.05 was considered significant. Results Ingestion of 180 mg ticagrelor reduced average aggregation responses from 71 to 16 A.U. (p<0.001) and the platelet reactivity index in the VASP-assay from 88 to 22 units (p<0.001) A clear dose-response was obtained after spiking whole blood with increasing amounts of PRP. After addition of PRP at a ratio of 1:10, platelet aggregation increased to 31±14 U. When assuming that one apheresis platelet concentrate (200 mL) typically contains a minimum of 2 x1011 platelets, the ratio of 1:10 corresponds to 0.5 units of apheresis platelet concentrates. A ratio of 1:5 – equivalent to 1 unit of platelet concentrates – increased ADP induced platelet aggregation to 41±14 U. Platelet aggregation increased further to 48±18 U following the addition of PRP at a ratio of 1:3, which corresponds to 1.5 units of platelet concentrates (figure 1). All comparisons were significant at p<0.01. Conclusion Platelets dose-dependently improved ex vivo platelet aggregation of subjects after a loading dose of 180 mg of ticagrelor. It is estimated that > 2 units of apheresis platelet concentrates will be necessary to completely restore baseline platelet aggregation in the majority of patients. Point-of-care platelet function tests may be suitable tools to verify this concept in emergency patients and to estimate the extent of the reversal and de-risk on an individual patient’s level. Disclosures: No relevant conflicts of interest to declare.


Transfusion ◽  
2021 ◽  
Author(s):  
Valery J. Li ◽  
S. Lawrence Bailey ◽  
Jeffrey Miles ◽  
Chomkan Usaneerungrueng ◽  
Lydia Y. Fang ◽  
...  

Transfusion ◽  
2006 ◽  
Vol 46 (8) ◽  
pp. 1292-1299 ◽  
Author(s):  
Louis Thibault ◽  
Annie Beausejour ◽  
Marie Joelle de Grandmont ◽  
Real Lemieux ◽  
Jean-Francois Leblanc

Sign in / Sign up

Export Citation Format

Share Document